Find recorded content from ATMP Sweden here.
We have started an ATMP Sweden YouTube channel! The following is a summary of the videos we have uploaded and you will be able to find any updates here also. Make sure you follow us on LinkedIn to receive announcement about new videos.
The CAMP project ”Expansion of GMP Compliant Tumor Infiltrating Lymphocytes (TILs) in Xuri bioreactor” presents an update of results in their project. Stina Wickström (Karolinska Institutet), Katrin Markland (Vecura) and Bill Shingleton (Cytiva) present results on production and use of Tumor Infiltrating Lymphocytes for clinical use against malignant melanoma. Treatment of metastatic malignant melanoma patients, who no longer responded to other types of cancer treatment, with Tumor Infiltrating Lymphocytes (TILs) and Dendritic Cells (DCs) has shown long term survival and remission with three severely ill patients in complete or near complete remission of the cancer. Presentation slides can be found on their project page.
NextGenNK gives an update on the world leading research and product development activities going on within the Competence Center. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners towards development of next generation NK cell-based cancer immunotherapies. Hans-Gustaf Ljunggren presents here the history of NK cell research and product development in Sweden as well as our goals for the future. Find out more on their website.
The Swelife-ATMP project SDP4 ”Opportunities and challenges for Sweden to become internationally leading in the field of gene therapy” present their final report including needs and initiatives towards connecting Sweden’s strong position with small companies to the manufacture capbilities they need to succeed in bringing their therapies to patients. Hear from project lead and Medical Advisor at Pfizer, Christian Gerdesköld, Linnea Enstedt and Jim Lund from the Research Institutes of Sweden (RISE) and Karin Agerman from the leading Gene Therapy company in the Nordics, Combigene. The project has produced a final report that is available on their project page.
The Swelife-ATMP project SDP5 (SWECARNET) introduces CAR-T development and implementation in Sweden and then interviews Sweden’s first CAR T patient and Gunilla Enblad, the first physician in Europe to treat a patient with CAR T, a medicine developed in her laboratory. Listen to hear patient perspectives on the implementation and use of CAR T and discussion between Stephan Mielke and Gunilla on the challenges of CAR T implementation and where energy and attention must be invested.
The Swelife-ATMP project SDP5 (SWECARNET) discusses their activities as Sweden’s National cancer network towards driving solutions for implementation of CAR T immunotherapy treatments for cancer in Sweden and future challenges. Stephan Mielke from Karolinska Hospital explains the progression of cancer treatments and the progress made in the 20 years since discovery of ’T bodies’ in Israel to the gene/cell therapy product CAR T. Why was Sweden so early to develop a CAR T, invented the third generation CAR T and treating the first patient in Sweden in 2014, and yet is falling behind in bringing CAR Ts to standard of care? SWECARNET is driving implementation of CAR T by building a National network of investigators, physicians/healthcare, patients/families/care givers, industry/companies and authorities/regulators to support both development of CAR T and adoption into standard of care.